Introduction: Iron deficiency is a common condition, especially among patients with kidney and heart failure and inflammatory bowel disease. Intravenous iron is the preferred method of treatment in these patients, but it usually requires prolonged iron polymaltose infusions or multiple administrations of alternative preparations. The aim of the study was to confirm the safety and patient acceptance of ultrarapid iron polymaltose infusions as an alternative to slower treatments and ferric carboxymaltose. Method: An open-label, phase 4 safety study was conducted at a tertiary hospital, with consenting participants diagnosed with iron deficiency and requiring iron polymaltose up to 1,500 mg receiving the infusion over 15 min. The acute adverse event (AE) rates and their severities were compared to historical controls of 1- and 4-h iron polymaltose infusions from a retrospective study of 648 patients from the same study site. Delayed AEs as well as participant infusion acceptability were also studied. Results: Three hundred participants over a 2-year period received ultrarapid infusions of iron polymaltose with an acute AE rate of 18.7% and severe AE rate of 1.0%. The total and mild infusion AE rates were higher compared to those of slower infusions (p #x3c; 0.001), but comparable for moderate and severe AEs. Delayed reactions occurred in 12.5% of participants, with over 95% of them preferring repeat ultrarapid infusions if required again. Conclusion: Iron polymaltose can be safely infused at ultrarapid rates when compared to slower infusions, with similar safety to ferric carboxymaltose, offering greater convenience for patients and reduced healthcare costs.
GE Port J Gastroenterol

中文翻译：

---

超快速铁聚麦芽糖输注对于缺铁症的管理是安全的

简介：缺铁是一种常见病症，尤其是在患有肾衰竭和心力衰竭以及炎症性肠病的患者中。静脉注射铁剂是这些患者的首选治疗方法，但通常需要长时间输注多麦芽糖铁剂或多次服用替代制剂。该研究的目的是确认超快速多麦芽糖铁输注作为较慢治疗和羧基麦芽糖铁的替代方案的安全性和患者接受度。方法：一项开放标签的 4 期安全性研究在一家三级医院进行，参与者同意被诊断患有缺铁症，需要在 15 分钟内输注高达 1,500 毫克的聚麦芽糖铁。将急性不良事件 (AE) 率及其严重程度与来自同一研究地点的 648 名患者的回顾性研究中 1 小时和 4 小时铁聚麦芽糖输注的历史对照进行了比较。还研究了延迟 AE 以及参与者输液可接受性。结果： 300 名参与者在 2 年期间接受超快速输注多麦芽糖铁，急性 AE 率为 18.7%，严重 AE 率为 1.0%。与较慢输注相比，总和轻度输注 AE 率更高 ( p#x3c; 0.001)，但对于中度和重度 AE 具有可比性。延迟反应发生在 12.5% 的参与者中，其中超过 95% 的人更愿意在需要时重复超快速输注。结论：与慢速输注相比，聚麦芽糖铁可以超快速输注安全，与羧基麦芽糖铁具有相似的安全性，为患者提供更大的便利并降低医疗成本。
GE Port J 胃肠醇